Journal of Vaccine Research, 2025, Vol.15, No.1, 34-44 http://medscipublisher.com/index.php/jvr 42 Chaturvedi R., and Sharma A., 2025, Key facets for the elimination of vector-borne diseases filariasis, leishmaniasis, and malaria, ACS Infectious Diseases, 11(2): 287-304. https://doi.org/10.1021/acsinfecdis.4c00431 Coughlan, L., 2020, Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines, Frontiers in Immunology, 11: 909. https://doi.org/10.3389/fimmu.2020.00909 De Souza W.M., and Weaver S.C., 2024, Effects of climate change and human activities on vector-borne diseases, Nature Reviews, Microbiology, 22(8): 476-491. https://doi.org/10.1038/s41579-024-01026-0 Fatima M., Park P., and Hong K., 2024, Clinical advancements in mRNA vaccines against viral infections, Clinical Immunology, 271: 110424. https://doi.org/10.1016/j.clim.2024.110424 Fouque F., and Reeder J.C., 2019, Impact of past and on-going changes on climate and weather on vector-borne diseases transmission: a look at the evidence, Infectious Diseases of Poverty, 8(1): 51. https://doi.org/10.1186/s40249-019-0565-1 Gebre M., Brito L., Tostanoski L., Edwards D., Carfi A., and Barouch D., 2021, Novel approaches for vaccine development, Cell, 184: 1589-1603. https://doi.org/10.1016/j.cell.2021.02.030 Hale G., 2023, Flaviviruses and the traveler: around the world and to your stage, a review of west nile, yellow fever, dengue, and zika viruses for the practicing pathologist, Modern Pathology, 36(6): 100188. https://doi.org/10.1016/j.modpat.2023.100188 Hamisi M.A., Asri N.A.M., Yassim A.S.M., and Suppian R., 2024, A systematic review on malaria and Tuberculosis (TB) vaccine challenges in sub-saharan African clinical trials, PLoS One, 20(1): e0317233. https://doi.org/10.1371/journal.pone.0317233 Heaton P.M., 2020, Challenges of developing novel vaccines with particular global health importance, Frontiers in Immunology, 11: 517290. https://doi.org/10.3389/fimmu.2020.517290 Huang Z., Zhang Y., Li H., Zhu J., Song W., Chen K., Zhang Y., and Lou Y., 2023, Vaccine development for mosquito-borne viral diseases, Frontiers in Immunology, 14: 1161149. https://doi.org/10.3389/fimmu.2023.1161149 Kanokudom S., Assawakosri S., Suntronwong N., Auphimai C., Nilyanimit P., Vichaiwattana P., Thongmee T., Yorsaeng R., Srimuan D., Thatsanatorn T., Klinfueng S., Sudhinaraset N., Wanlapakorn N., Honsawek S., and Poovorawan Y., 2021, Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine, Vaccines, 10(1): 86. https://doi.org/10.3390/vaccines10010086 Kennedy R., Ovsyannikova I., Palese P., and Poland G., 2020, Current challenges in vaccinology, Frontiers in Immunology, 11: 1181. https://doi.org/10.3389/fimmu.2020.01181 Kim K., 2019, Current challenges in the development of vaccines and drugs against emerging vector-borne diseases, Current Medicinal Chemistry, 26(16): 2974-2986. https://doi.org/10.2174/0929867325666181105121146 Kim Y.A., Mousavi K., Yazdi A., Zwierzyna M., Cardinali M., Fox D., Peel T., Coller J., Aggarwal K., and Maruggi G., 2023, Computational design of mRNA vaccines, Vaccine, 42(7): 1831-1840. https://doi.org/10.1016/j.vaccine.2023.07.024 Kowalzik F., Schreiner D., Jensen C., Teschner D., Gehring S., and Zepp F., 2021, mRNA-based vaccines, Vaccines, 9(4): 390. https://doi.org/10.3390/vaccines9040390 Kraemer M.U., Sinka M.E., Duda K.A., Mylne A.Q., Shearer F.M., Barker C.M., Moore C.G., Carvalho R.G., Coelho G.E., Van Bortel W., Hendrickx G., Schaffner F., Elyazar I.R., Teng H.J., Brady O.J., Messina J.P., Pigott D.M., Scott T.W., Smith D.L., Wint G.R., Golding N., and Hay S.I., 2015, The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus, eLife, 4: e08347. https://doi.org/10.7554/eLife.08347 Leong K., Tham S., and Poh C., 2025, Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications, Virology Journal, 22(1): 71. https://doi.org/10.1186/s12985-025-02645-6 Logiudice J., Alberti M., Ciccarone A., Rossi B., Tiecco G., De Francesco M., and Quiros-Roldan E., 2025, Introduction of vector-borne infections in europe: emerging and re-emerging viral pathogens with potential impact on one health, Pathogens, 14(1): 63. https://doi.org/10.3390/pathogens14010063 Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.Y., Tukhvatulin A., Zubkova O., Dzharullaeva A., Kovyrshina A., Lubenets N., Grousova D., Erokhova A., Botikov A., Izhaeva F., Popova O., Ozharovskaya T., Esmagambetov I., Favorskaya I., Zrelkin D., Voronina D., Shcherbinin D., Semikhin A., Simakova Y., Tokarskaya E., Egorova D., Shmarov M., Nikitenko N., Gushchin V., Smolyarchuk E., Zyryanov S., Borisevich S., Naroditsky B., and Gintsburg A., 2021, Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia, Lancet (London, England), 397(10275): 671-681. https://doi.org/10.1016/S0140-6736(21)00234-8 Li M.L., 2024, Advancements in mRNA vaccines for breast cancer treatment: current trends and future prospects, Journal of Vaccine Research, 14(3): 147-156 https://doi.org/10.5376/jvr.2024.14.0015
RkJQdWJsaXNoZXIy MjQ4ODYzNA==